TY - JOUR
KW - context of use assays
KW - Drug development
KW - human model systems
KW - microphysiological systems
KW - model-omics
KW - new alternative methods
KW - organoids
KW - organs-on-chip
KW - Pharmaceutical industry
AU - Kimberly A. Homan
AB - During the last decade, organoid and organs-on-chip technologies have significantly enhanced the ability to model human biology in vitro. For the pharmaceutical industry, this represents an opportunity to augment, or possibly replace, traditional preclinical animal studies with more clinically predictive tools. In the last few years, the marketplace for new human model systems has expanded rapidly. While pharma companies welcome the breadth of new options, ample choice can be paralyzing. Even for experts from the model developer community who are now filling the ranks in the industry, the pairing of the right model for a specific, fit-for-purpose biological question can be daunting. As a community, the adoption of these models can be hastened in the industry by publishing high dimensional datasets (e.g., multiomic, imaging, functional, etc.) on existing model systems, termed model-omics, and storing them in publicly accessible databases. This action will allow for quick cross-model comparisons and provide a sought-after rationale for either routine or fit-for-purpose use of organoids or organs-on-chip during drug development.
BT - Advanced Biology
DA - 2023
DO - 10.1002/adbi.202200334
IS - 6
LA - en
N2 - During the last decade, organoid and organs-on-chip technologies have significantly enhanced the ability to model human biology in vitro. For the pharmaceutical industry, this represents an opportunity to augment, or possibly replace, traditional preclinical animal studies with more clinically predictive tools. In the last few years, the marketplace for new human model systems has expanded rapidly. While pharma companies welcome the breadth of new options, ample choice can be paralyzing. Even for experts from the model developer community who are now filling the ranks in the industry, the pairing of the right model for a specific, fit-for-purpose biological question can be daunting. As a community, the adoption of these models can be hastened in the industry by publishing high dimensional datasets (e.g., multiomic, imaging, functional, etc.) on existing model systems, termed model-omics, and storing them in publicly accessible databases. This action will allow for quick cross-model comparisons and provide a sought-after rationale for either routine or fit-for-purpose use of organoids or organs-on-chip during drug development.
PY - 2023
EP - 2200334
ST - Industry Adoption of Organoids and Organs-on-Chip Technology
T2 - Advanced Biology
TI - Industry Adoption of Organoids and Organs-on-Chip Technology: Toward a Paradox of Choice
UR - https://onlinelibrary.wiley.com/doi/abs/10.1002/adbi.202200334
VL - 7
Y2 - 2025-05-01
SN - 2701-0198
ER -